TRICUSPID STENOSIS

Course overview

VERY LITTLE IS KNOWN ABOUT TRICUSPID VALVE WHEN COMPARED TO OTHER VALVES, AND TRICUSPID STENOSIS IS RARELY DESCRIBED. IT MOST OFTEN CO-EXISTS WITH MITRAL VALVE PATHOLOGY ESPECIALLY IN PATIENTS WITH RHEUMATIC HEART DISEASE. OTHER CAUSES OF TRICUSPID STENOSIS INCLUDE INFECTIVE ENDOCARDITIS, CARCINOID SYNDROME, SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), ANTIPHOSPHOLIPID ANTIBODY (APLA) SYNDROME, ATRIAL MYXOMAS, BLUNT TRAUMA, METASTASIS OF RENAL OR OVARIAN TUMORS, CONGENITAL ABNORMALITIES, FABRY’S DISEASE, WHIPPLE’S DISEASE, INTRAVENOUS LEIOMYOMATOSIS, VENTRICULOATRIAL SHUNTS, AND VALVULOPATHY ASSOCIATED WITH DRUGS LIKE FENFLURAMINE/PHENTERMINE AND METHYSERGIDE. THIS ACTIVITY DESCRIBES THE EVALUATION AND MANAGEMENT OF TRICUSPID STENOSIS AND HIGHLIGHTS THE ROLE OF THE INTERPROFESSIONAL TEAM IN IMPROVING CARE FOR AFFECTED PATIENTS.